InMed Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of proprietary small molecule drug candidates targeting the CB1 and CB2 receptors. The company operates through two primary segments: InMed Pharmaceuticals, which advances prescription-based products for diseases with high unmet medical needs, and BayMedica Commercial, which develops proprietary manufacturing technologies (such as the IntegraSyn biosynthesis platform) to produce and sell rare cannabinoids for the health and wellness industry. InMed's clinical pipeline is anchored by three core programs: INM-901, a small molecule candidate targeting Alzheimer's disease; INM-089, a selective dual CB1/CB2 agonist for dry age-related macular degeneration (AMD); and INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trials for the treatment of epidermolysis bullosa.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the proprietary small-molecule drug candidate INM-901 for the treatment of Alzheimer's disease. Focus areas include executing IND-enabling pharmacology and toxicology studies, scaling up drug substance and product manufacturing (CMC activities), and engaging clinical experts to design first-in-human trials.
Expected impact: Establish clinical readiness and transition the company's lead Alzheimer's asset into human clinical evaluations.
Developing the proprietary small-molecule drug candidate INM-089 for the treatment of dry age-related macular degeneration (AMD). Activities include dose-ranging, pharmacokinetic studies, and preparing processes for IND-enabling studies.
Expected impact: Define the regulatory pathway and prepare the asset for IND-enabling toxicology and pharmacology studies.
Actively seeking development and commercial partnerships to further advance the completed Phase 2 epidermolysis bullosa (EB) program (INM-755) and to license non-core drug candidates.
Expected impact: Secure non-dilutive funding, validate the proprietary cannabinoid platform, and offset pipeline development costs.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Conducting INM-901 neuroinflammation studies in Stem Pharm's proprietary 3D human brain organoid models of Alzheimer's disease to discover and validate therapeutic targets.
Terms: Not publicly disclosed.
Collaborating on the project 'Pharmacological characterization of phytocannabinoids and the endocannabinoid system' to investigate the therapeutic effects of rare cannabinoid analogs in neurodegenerative diseases.
Terms: Supported by an Alliance grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) with InMed as the named industry partner.
Collaborating with the laboratory of Dr. Mauro Maccarrone to screen InMed's novel cannabinoid analogs and investigate their pharmacological properties and potential therapeutic uses.
Terms: Not publicly disclosed.
Definitive all-stock merger agreement to combine InMed's public market infrastructure with Mentari's migraine prevention pipeline (MT-001 and MT-002). Upon closing, the combined entity will operate as Mentari Therapeutics and trade on Nasdaq under a new ticker symbol.
Terms: All-stock transaction. Pre-merger InMed shareholders are expected to own approximately 1.51% of the combined company (subject to net cash adjustments), which has a pro forma equity value of approximately $421.4 million, inclusive of a concurrent $290 million private placement.